Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

BASF and Cardiol Therapeutics recommended buys; TUI rides momentum

BASF (OTCQX:BASFY) shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the stock did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see ...
Fabian Lorenz | April 10, 2024 |

Is this stunning 'evidence' that NervGen has the goods?

This could be the signal that tiny NervGen Pharma Corp. (TSX-V:NGEN; OTCQX:NGENF) is destined to be one of the top performing biotech startup stocks this year. It came in a seemingly innocuous podcast interview about the company’s ongoing Phase 1b/2...
Knox Henderson | February 1, 2024 |

Buzz on the Bullboards: Good stocks with bad publicity

It was hedge fund legend Ray Dalio who said: “He who lives by the crystal ball will eat shattered glass.” Many stock markets may have seen a higher start to the year so far, but there is far from a universal sentiment across the sectors, with s...
Jonathon Brown | January 25, 2024 |

Theralase is raising up to $5.3M to complete bladder cancer study

Theralase Technologies is announcing a brokered financing raise for up to C$5.3 million Proceeds of the financing will be used to further the Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study Ruvidar is designed to destroy solid core tum...
Coreena Robertson | November 6, 2023 |

It’s Time to Start Talking about the Elephant in the Room

By Jonathan Goodman We at Dundee Goodman Merchant Partners have spent most of our working lives in the resource industry. Collectively we are money managers, geologists, engineers, mining operators, and natural resource/mining bankers. Moreover, all of us are person...
Research | April 5, 2023 |

Buzz on the Bullboards: Energy Remains in Focus During Ukraine Crisis

(File image.) The cost of living just keeps getting more expensive. This week saw headlines in the news around the rise in US inflation, up 8.5% over the year to the end of March, to hit its highest rate since 1981. The war in Ukraine drove up energy costs f...
Stockhouse Editorial | April 13, 2022 |

Buzz on the Bullboards: The Top Last-Minute Movers of 2021

Expecting the markets to be relaxed heading into the holidays? Hardly. Many investors and brokers know that this is the time to shine. With every twist and turn the global economy has been throwing our way, the right move is staying active. This past week, it seems ma...
Stockhouse Editorial | December 7, 2021 |

Buzz on the Bullboards: ‘Tis the Season for a Rebound?

Once the American Thanksgiving passes, the mood in North American markets seems to shift dramatically as investors contend with holidays, gifts, and vacations on one hand, with the end of their fiscal years on the other. Companies also look to end the calendar year on...
Stockhouse Editorial | December 1, 2021 |

The Medical Device Co. That’s on the Cutting-Edge of Advancing Heart Disease Treatment

Back in early September , we introduced our Stockhouse audience to a unique play in the emerging medical tech space – Neovasc Inc. ( TSX: NVCN , OTCQB: NVCN , Forum ). The company develops, manufactures, and markets products for the rapidly growing cardiovascular marke...
Dave Jackson | November 29, 2021 |

Disrupting the Cannabinoid Industry with Science and Innovation

(Click image to play video) Get to know Toronto-based Avicanna Inc. (AVCN) ( TSX.AVCN , OTC: AVCNF , Forum ) – a biopharmaceutical company developing and driving biopharmaceutical advancements of plant-derived cannabinoid-based products, and the man at the h...
Dave Jackson | May 6, 2021 |
1 2 3 4